Evaluation of CD86 gene polymorphism at + 1057 position in liver transplant recipients

Efficient T cell–APC interaction requires the participation of primary and co-stimulatory signals. The main co-stimulatory pathway involves the interaction of CD80 and CD86, expressed on the APCs, with their T cell counter-receptor, CD28 and CTLA-4. Recently, a G to A transition has been described a...

Full description

Saved in:
Bibliographic Details
Published in:Transplant immunology 2005-10, Vol.15 (1), p.69-74
Main Authors: Marín, L.A., Moya-Quiles, M.R., Miras, M., Muro, M., Minguela, A., Bermejo, J., Ramírez, P., García-Alonso, A.M., Parrilla, P., Alvarez-López, M.R.
Format: Article
Language:English
Subjects:
Acute Disease
Acute rejection
Adult
B7-2 Antigen - genetics
CD86
Chronic Disease
Chronic rejection
Female
Graft Rejection - genetics
Graft survival
Graft Survival - genetics
Humans
Liver Transplantation - immunology
Male
Middle Aged
Polymorphism, Single Nucleotide
Single nucleotide polymorphism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efficient T cell–APC interaction requires the participation of primary and co-stimulatory signals. The main co-stimulatory pathway involves the interaction of CD80 and CD86, expressed on the APCs, with their T cell counter-receptor, CD28 and CTLA-4. Recently, a G to A transition has been described at position + 1057 of the CD86 gene, located in their cytoplasmic tail. CD86 polymorphism was analyzed by sequence based typing in DNA samples obtained from 205 liver transplant recipients. Acute rejection and chronic rejection were diagnosed based upon conventional clinical, biochemical and histological criteria. The study of CD86 + 1057 (G/A) polymorphism revealed that recipients bearing the A allele or the AA genotype have a reduced risk of acute rejection. In fact, the AA genotype was absent in the group of patients showing acute rejection episodes, whereas its frequency in those patients without acute rejection episodes was 8.8% ( P = 0.009, OR = 0.07). This polymorphism did not reveal any association with the incidence of chronic rejection, but patients bearing the AA genotype showed a higher graft survival rate (83.3%) than those bearing the GA genotype (49.3%) or GG genotype (56.5%). The results of the present report suggest that the CD86 AA genotype at + 1057 position could be involved in liver transplant acceptance, given that its presence is related to a decrease of acute rejection frequency and to a graft survival increase.
ISSN:0966-3274
1878-5492
DOI:10.1016/j.trim.2005.04.003